{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:28:17Z","timestamp":1790011697090,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cyto.2024.156531","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T23:37:17Z","timestamp":1706744237000},"page":"156531","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Increased tissue expression of IL-31 in patients with psoriasis"],"prefix":"10.1016","volume":"176","author":[{"given":"Rachot","family":"Wongjirattikarn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nipon","family":"Chaisuriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suteeraporn","family":"Chaowattanapanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piti","family":"Ungarreevittaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirawan","family":"Poosekeaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengkart","family":"Winaikosol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charoen","family":"Choonhakarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narachai","family":"Julanon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eakkapol","family":"Utchariyaprasit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kittisak","family":"Sawanyawisuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cyto.2024.156531_b0005","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","article-title":"Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence","volume":"133","author":"Parisi","year":"2013","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.cyto.2024.156531_b0010","first-page":"7","article-title":"Current knowledge on psoriasis and autoimmune diseases","volume":"6","author":"Ayala-Font\u00e1nez","year":"2016","journal-title":"Psoriasis Auckl. NZ."},{"key":"10.1016\/j.cyto.2024.156531_b0015","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2024.156531_b0020","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ejp.768","article-title":"Pruritus in psoriasis: An update","volume":"20","author":"Szepietowski","year":"2016","journal-title":"Eur. J. Pain Lond. Engl."},{"key":"10.1016\/j.cyto.2024.156531_b0025","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaci.2005.10.046","article-title":"IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T cells in patients with atopic dermatitis","volume":"117","author":"Bilsborough","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2024.156531_b0030","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jaci.2008.05.047","article-title":"Correlation of IL-31 serum levels with severity of atopic dermatitis","volume":"122","author":"Raap","year":"2008","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2024.156531_b0035","first-page":"285","article-title":"IL-31 significantly correlates with disease activity and Th2 cytokine levels in children with atopic dermatitis","volume":"23","author":"Raap","year":"2012","journal-title":"Pediatr. Allergy Immunol. Off. Publ. Eur. Soc. Pediatr. Allergy Immunol."},{"key":"10.1016\/j.cyto.2024.156531_b0040","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.jaci.2005.10.033","article-title":"IL-31: a new link between T cells and pruritus in atopic skin inflammation","volume":"117","author":"Sonkoly","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2024.156531_b0045","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3389\/fimmu.2019.01383","article-title":"Role of the pruritic cytokine IL-31 in autoimmune skin diseases","volume":"10","author":"Gibbs","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cyto.2024.156531_b0050","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/j.jaci.2017.10.045","article-title":"IL-31: A new key player in dermatology and beyond","volume":"141","author":"Ba\u011fci","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2024.156531_b0055","doi-asserted-by":"crossref","first-page":"3858032","DOI":"10.1155\/2018\/3858032","article-title":"IL-33\/IL-31 axis: A potential inflammatory pathway","volume":"2018","author":"Di Salvo","year":"2018","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.cyto.2024.156531_b0060","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/exd.13533","article-title":"Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis","volume":"27","author":"Nakashima","year":"2018","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cyto.2024.156531_b0065","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2147\/CCID.S257647","article-title":"IL-33\/13 axis and IL-4\/31 axis play distinct roles in inflammatory process and itch in psoriasis and atopic dermatitis","volume":"13","author":"Bodoor","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"10.1016\/j.cyto.2024.156531_b0070","doi-asserted-by":"crossref","first-page":"e05621","DOI":"10.1016\/j.heliyon.2020.e05621","article-title":"Increased serum IL-31 levels in chronic spontaneous urticaria and psoriasis with pruritic symptoms","volume":"6","author":"Chaowattanapanit","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.cyto.2024.156531_b0075","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2340\/00015555-1191","article-title":"IL-31 expression by inflammatory cells is preferentially elevated in atopic dermatitis","volume":"92","author":"Nobbe","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.cyto.2024.156531_b0080","first-page":"e3465","article-title":"Semi-quantitative determination of protein expression using immunohistochemistry staining and analysis: an integrated protocol","volume":"9","author":"Crowe","year":"2019","journal-title":"Bio-Protoc."},{"key":"10.1016\/j.cyto.2024.156531_b0085","doi-asserted-by":"crossref","first-page":"8406","DOI":"10.3390\/ijms21218406","article-title":"Molecular and cellular mechanisms of itch in psoriasis","volume":"21","author":"Komiya","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cyto.2024.156531_b0090","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jaci.2006.07.015","article-title":"Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis","volume":"118","author":"Neis","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.cyto.2024.156531_b0095","doi-asserted-by":"crossref","first-page":"17797","DOI":"10.1038\/s41598-017-18187-z","article-title":"Increased plasma IL-17, IL-31, and IL-33 levels in chronic spontaneous urticaria","volume":"7","author":"Lin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cyto.2024.156531_b0100","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0625.2010.01067.x","article-title":"Increased levels of serum IL-31 in chronic spontaneous urticaria","volume":"19","author":"Raap","year":"2010","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.cyto.2024.156531_b0105","doi-asserted-by":"crossref","first-page":"426","DOI":"10.5114\/pdia.2015.56097","article-title":"Itching sensation in psoriatic patients and its relation to body mass index and IL-17 and IL-31 concentrations","volume":"32","author":"Czarnecka-Operacz","year":"2015","journal-title":"Postepy Dermatol. Alergol."},{"key":"10.1016\/j.cyto.2024.156531_b0110","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00403-012-1293-6","article-title":"Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients","volume":"305","author":"Narbutt","year":"2013","journal-title":"Arch. Dermatol. Res."},{"key":"10.1016\/j.cyto.2024.156531_b0115","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment","volume":"45","author":"Ogawa","year":"2018","journal-title":"J. Dermatol."},{"issue":"184","key":"10.1016\/j.cyto.2024.156531_b0120","first-page":"3526","article-title":"Antimicrobial peptides human beta-defensins and cathelicidin LL-37 induce the secretion of a pruritogenic cytokine IL-31 by human mast cells","volume":"2010","author":"Niyonsaba","year":"1950","journal-title":"J. Immunol. Baltim. Md"},{"key":"10.1016\/j.cyto.2024.156531_b0125","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5021\/ad.2012.24.2.126","article-title":"Cathelicidin LL-37: an antimicrobial peptide with a role in inflammatory skin disease","volume":"24","author":"Reinholz","year":"2012","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.cyto.2024.156531_b0130","doi-asserted-by":"crossref","first-page":"e4725","DOI":"10.1371\/journal.pone.0004725","article-title":"Beta-defensin-2 protein is a serum biomarker for disease activity in psoriasis and reaches biologically relevant concentrations in lesional skin","volume":"4","author":"Jansen","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.cyto.2024.156531_b0135","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420907186","article-title":"A potential inflammatory role of IL-31 in psoriatic arthritis: A correlation with Th17 cytokine profile","volume":"34","author":"Bautista-Herrera","year":"2020","journal-title":"Int. J. Immunopathol. Pharmacol."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624000346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624000346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:49:37Z","timestamp":1760910577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466624000346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":27,"alternative-id":["S1043466624000346"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156531","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increased tissue expression of IL-31 in patients with psoriasis","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156531","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"156531"}}